Cardinal Health, Inc. (CAH)
Pre-market:
| Previous close | 103.04 |
| Open | 102.25 |
| Bid | 100.07 x 1200 |
| Ask | 110.77 x 800 |
| Day's range | 100.56 - 103.10 |
| 52-week range | 77.56 - 116.04 |
| Volume | |
| Avg. volume | 2,244,381 |
| Market cap | 24.851B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 40.54 |
| EPS (TTM) | 2.52 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 2.00 (1.96%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | 115.07 |
- Reuters
Cardinal Health lifts 2024 profit view on demand for costly specialty drugs
Cardinal Health raised its annual profit forecast on Thursday, betting on strength in its pharmaceutical unit selling costly specialty drugs used to treat complex conditions such as cancer. Drug distributors, including rival Cencora, have been benefiting from growing sales of specialty medicines at a time when prices of generic, or copycat, versions have been falling due to intense competition. Cardinal now expects 2024 adjusted earnings in the range of $7.30 to $7.40 per share, compared with $7.20 to $7.35 per share forecast previously.
GuruFocus.comCardinal Health Inc (CAH) Q3 Earnings: Surpasses Analyst EPS Forecasts and Raises FY24 Guidance
A Detailed Look at Cardinal Health's Financial Performance and Strategic Highlights
PR NewswireCardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance
Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were $1.05, which included a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution (GMPD) segment as a result of the reallocation of goodwill related to the reporting structure update.
